The blood sparing effect and the safety of aprotinin compared to tranexamic acid in paediatric cardiac surgery

被引:71
作者
Breuer, Tamas [1 ,4 ]
Martin, Klaus [1 ]
Wilhelm, Markus [1 ]
Wiesner, Gunther [1 ]
Schreiber, Christian [2 ]
Hess, John [3 ]
Lange, Ruediger [2 ]
Tassani, Peter [1 ]
机构
[1] Clin Tech Univ Munich, German Heart Ctr, Inst Anasthesiol, D-80636 Munich, Germany
[2] Clin Tech Univ Munich, German Heart Ctr, Dept Cardiovasc Surg, D-80636 Munich, Germany
[3] Clin Tech Univ Munich, German Heart Ctr, Dept Paediat Cardiol & Congenital Heart Defects, D-80636 Munich, Germany
[4] Semmelweis Univ, Dept Cardiol, H-1085 Budapest, Hungary
关键词
Congenital heart defects; Paediatric cardiac surgery; Antifibrinolytics; Blood transfusion; Morbidity; Mortality; CRITICALLY-ILL CHILDREN; METAANALYSIS; HEMORRHAGE; EFFICACY; SEIZURES; OUTCOMES; TRIALS;
D O I
10.1016/j.ejcts.2008.09.038
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Recently, the safety of aprotinin administration during open-heart surgery has been debated. The aim of the study was to compare the blood sparing effect and the side effects of aprotinin and tranexamic acid in paediatric cardiac surgery patients. Methods: Perioperative data of 199 consecutive patients weighing less than 20 kg undergoing open-heart cardiac surgery were prospectively collected between September 2005 and June 2006. During the first 5 months, 85 patients received aprotinin (group A); in the next 5 months, 114 patients were treated with tranexamic acid (group T). Except for antifibrinolytic therapy, the anaesthesiotogical and surgical protocols remained unchanged. Postoperative complications and in-hospital and 1-year mortality were considered as outcome parameters. Results: The descriptive parameters and the intraoperative parameters were well comparable in the two groups. The blood toss was significantly lower in group A compared to group Tat 6 h [55 (35-82.5) vs 70 (45-100) ml, p = 0.031], but not at 12 and 24 h after operation. The incidence [9 (11%) vs 25 (22%), p = 0.035] and the amount of red blood cell transfusion during the first 24 h after surgery were also significantly tower in group A (0.1 +/- 0.4 vs 0.3 +/- 0.6 unit, p = 0.036). There were significantly less rethoracotomies in group A [2 (2.4%) vs 11 (9.6%), p, = 0.039]. We found no difference in the incidence of the postoperative complications and in-hospital and 1-year mortality. There was a tendency for a higher incidence of seizures in group T [4 (3.5%) vs 0 (0%), p = 0.14]. Conclusions: Aprotinin administration bears no additional risks compared to tranexamic acid and it has a stronger blood sparing effect in paediatric cardiac surgery. There were fewer rethoracotomies and less postoperative red blood cell transfusion in patients who received aprotinin. (C) 2008 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:167 / 171
页数:5
相关论文
共 25 条
[1]   Modified RIFLE criteria in critically ill children with acute kidney injury [J].
Akcan-Arikan, A. ;
Zappitelli, M. ;
Loftis, L. L. ;
Washburn, K. K. ;
Jefferson, L. S. ;
Goldstein, S. L. .
KIDNEY INTERNATIONAL, 2007, 71 (10) :1028-1035
[2]   Avoiding transfusions in children undergoing cardiac surgery: A meta-analysis of randomized trials of aprotinin [J].
Arnold, DM ;
Fergusson, DA ;
Chan, AKC ;
Cook, RJ ;
Fraser, GA ;
Lim, W ;
Blajchman, MA ;
Cook, DJ .
ANESTHESIA AND ANALGESIA, 2006, 102 (03) :731-737
[3]   Aprotinin is safe in pediatric patients undergoing cardiac surgery [J].
Backer, Carl L. ;
Kelle, Angela M. ;
Stewart, Robert D. ;
Suresh, Sunitha C. ;
Ali, Farah N. ;
Cohn, Richard A. ;
Seshadri, Roopa ;
Mavroudis, Constantine .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2007, 134 (06) :1421-1428
[4]   Pro: Aprotinin has a good efficacy and safety profile relative to other alternatives for prevention of bleeding in cardiac surgery [J].
Body, Simon C. ;
Mazer, C. David .
ANESTHESIA AND ANALGESIA, 2006, 103 (06) :1354-1359
[5]   Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery [J].
Brown, Jeremiah R. ;
Birkmeyer, Nancy J. O. ;
O'Connor, Gerald T. .
CIRCULATION, 2007, 115 (22) :2801-2813
[6]   Reexploration for hemorrhage following coronary artery bypass grafting - Incidence and risk factors [J].
Dacey, LJ ;
Munoz, JJ ;
Baribeau, YR ;
Johnson, ER ;
Lahey, SJ ;
Leavitt, BJ ;
Quinn, RD ;
Nugent, WC ;
Birkmeyer, JD ;
O'Connor, GT .
ARCHIVES OF SURGERY, 1998, 133 (04) :442-446
[7]   A comparison of aprotinin and lysine analogues in high-risk cardiac surgery [J].
Fergusson, Dean A. ;
Hebert, Paul C. ;
Mazer, C. David ;
Fremes, Stephen ;
MacAdams, Charles ;
Murkin, John M. ;
Teoh, Kevin ;
Duke, Peter C. ;
Arellano, Ramiro ;
Blajchman, Morris A. ;
Bussieres, Jean S. ;
Cote, Dany ;
Karski, Jacek ;
Martineau, Raymond ;
Robblee, James A. ;
Rodger, Marc ;
Wells, George ;
Clinch, Jennifer ;
Pretorius, Roanda .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (22) :2319-2331
[8]   Tranexamic acid, a widely used Antifibrinolytic agent, causes convulsions by a γ-aminobutyric acidA receptor antagonistic effect [J].
Furtmüller, R ;
Schlag, MG ;
Berger, M ;
Hopf, R ;
Huck, S ;
Sieghart, W ;
Redl, H .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 301 (01) :168-173
[9]  
Hörl WH, 2000, BRIT J ANAESTH, V84, P3
[10]   The effect of short-term antifibrinolytic therapy on experimental vasospasm [J].
Iplikcioglu, AC ;
Berkman, MZ .
SURGICAL NEUROLOGY, 2003, 59 (01) :10-17